Here is How Peptide Drugs Can Work Without a Perfect Alpha Helix Structure

A new Nature Chemistry study shows that peptide drugs can still activate GPCR receptors even without forming a perfect alpha helix. This discovery challenges traditional drug design and opens new possibilities for safer, more selective peptide-based medicines.

This blog is based on the findings from the research paper “Potent and biased agonists of class B1 GPCRs from a heterochiral design strategy,” published in 2026 in the journal Nature Chemistry by researchers at the University of Wisconsin–Madison.

The main research team behind the study came from the University of Wisconsin–Madison, specifically the Department of Chemistry, working in the lab of Professor Samuel H. Gellman.

Key authors included behind “Potent and biased agonists of class B1 GPCRs from a heterochiral design strategy,”

• Ruslan Gibadullin – graduate student
• Lauren My-Linh Tran – graduate student
• Jiani Niu – graduate student
• Rylie K. Morris – graduate student
• Ariel J. Kuhn – postdoctoral researcher
• John A. Mannone – graduate student
• Tae Wook Kim – researcher
• Giuseppe Deganutti – computational collaborator (modeling/simulations)
• Samuel H. Gellman – principal investigator (lab head)

The core idea of this blog,

• Peptides are short chains of amino acids.
• Scientists used to believe that for these chains to properly activate receptors in the body, they needed to adopt a very specific and stable shape, often a spiral-like structure called an alpha helix.
• However, recent findings from researchers at the University of Wisconsin–Madison suggest something different. They discovered that peptide molecules can still effectively activate receptors even when their structure is intentionally altered and made less uniform. In other words, peptides do not always need a perfectly fixed shape to deliver biological signals.
• As long as the key chemical features needed for receptor interaction are present, these flexible or “imperfect” versions of peptides can still produce strong effects on cells, sometimes with nearly the same level of activity as the original form, but with more selective signaling behavior.

For a long time, biology has been taught with a simple but powerful idea: shape determines function. In the world of medicines, especially those made from peptides, this idea has guided almost everything researchers do. If a molecule wants to activate a receptor in the body, it is expected to fold into a very specific three-dimensional form. Change that form, and the message should fail.

But recent research from scientists at the University of Wisconsin–Madison suggests that this picture is incomplete. Some peptide drugs, it turns out, can still work even when their “ideal” structure is disrupted. Even more interestingly, these altered molecules may sometimes behave in a more controlled and selective way than their natural counterparts.

This discovery is reshaping how scientists think about hormone signaling, receptor activation, and the future of drug design.

To understand why this is such a big deal, we first need to understand how the body uses molecular communication in the first place.

The Body’s Communication System

Every second of your life, billions of cells are talking to each other. They do not use words or sound, but chemical signals. Hormones, neurotransmitters, and peptides travel through the body carrying instructions: grow, store energy, release energy, build bone, reduce appetite, or increase blood sugar.

These messages are essential for survival. Without them, the body would be unable to coordinate even basic processes like breathing, digestion, or maintaining temperature.

At the center of this communication system are specialized proteins called receptors. A receptor sits on the surface of a cell like a sensor. When the right molecule binds to it, the receptor changes shape and triggers a response inside the cell.

This is where drug design becomes important. Many medicines work by either imitating or blocking these natural signals. If a drug can successfully bind to a receptor and activate it, it can influence biological processes in powerful ways.

Peptides: Nature’s Message Carriers

A large number of hormones in the body are peptides. Peptides are short chains of amino acids—the same building blocks that form proteins. Unlike large, complex proteins, peptides are relatively small and flexible, which allows them to act quickly as signaling molecules.

Several modern blockbuster drugs are peptide-based. Medicines such as the diabetes and obesity treatments Ozempic and Mounjaro, as well as the osteoporosis treatment Forteo, all work by mimicking natural peptide hormones in the body.

These drugs are effective because they essentially “speak the same language” as the body’s own signaling systems.

But there has always been a catch.

The Old Assumption: Shape Is Everything

For decades, scientists believed that peptide hormones needed to adopt very specific shapes in order to activate their receptors properly. Among the most important of these shapes is the alpha helix, a spiral-like structure that many peptides form when they bind to their targets.

You can imagine the alpha helix as a tightly coiled spring. When a peptide folds into this structure, certain parts of the molecule are positioned in just the right way to interact with a receptor.

This idea became a foundation of drug design. If researchers could stabilize the helix, they could improve drug performance. If they disrupted it, the drug would likely stop working.

It was a neat and satisfying model: precise shape leads to precise function.

However, biology rarely stays neat for long.

A Question That Changed Everything

At the University of Wisconsin–Madison, researchers in the Gellman group began asking a simple but provocative question:

What happens if we intentionally make it harder for a peptide to form its ideal helical shape?

Conventional wisdom predicted a clear outcome. If the helix is essential, weakening it should reduce or eliminate activity.

But instead of confirming this expectation, the experiments revealed something unexpected.

The peptides still worked.

Not only did they still activate their target receptors, but in some cases they did so with surprising efficiency.

This result forced scientists to reconsider what exactly was required for receptor activation.

Breaking the Helix on Purpose

To test this idea, researchers modified natural peptide hormones by introducing structural changes that make the alpha helix harder to form.

One of the key strategies involved replacing some of the natural amino acids with mirror-image versions known as D-amino acids. In nature, most proteins are made from L-amino acids, which fit together in a consistent orientation. D-amino acids disrupt that regular structure, making it more difficult for the peptide to maintain a stable spiral.

When these changes were introduced into hormones such as glucagon, which plays a role in regulating blood sugar, something surprising happened: the modified peptides still activated the glucagon receptor effectively.

This was not an isolated case. Similar results were observed when researchers modified a segment of parathyroid hormone, a key regulator of calcium and bone metabolism. This hormone is the basis for drugs used in treating osteoporosis.

Even with a weakened ability to form a perfect helix, the modified molecules continued to “speak” to their receptors.

Rethinking the Lock-and-Key Idea

The traditional way of thinking about molecular interactions is often described as a lock-and-key model. The receptor is the lock, and the molecule is the key. If the key is not shaped correctly, it should not open the lock.

But these new findings suggest the reality is more flexible.

Instead of a rigid lock-and-key system, receptor activation may behave more like a dynamic handshake. What matters is not a single perfect shape, but a set of key interactions that can occur even if the molecule is flexible or partially disordered.

In other words, the receptor may not require a perfect spiral at every moment. It may only need certain critical contact points to be present often enough during the interaction.

This changes how scientists think about molecular recognition.

Molecules Are Not Static Objects

One of the most important insights from modern biochemistry is that molecules are not rigid structures. They are constantly moving, twisting, and sampling different shapes.

Even when scientists capture their structure using powerful imaging methods, such as cryo-electron microscopy, what they see is only a snapshot in time.

Inside the body, these molecules behave more like dynamic systems than fixed objects.

The new research suggests that this flexibility is not just background noise—it may actually be part of how biological signaling works.

A peptide does not need to “lock into” one perfect shape. Instead, it may function through a shifting ensemble of shapes that collectively produce the correct signal.

A New Kind of Drug Behavior: Biased Signaling

Perhaps the most exciting aspect of this discovery is not just that modified peptides still work, but that they may work differently in a useful way.

When a peptide binds to a receptor, it can trigger multiple internal signaling pathways. Some of these pathways produce the desired therapeutic effect, while others may lead to unwanted side effects.

If a drug activates all pathways equally, it can be effective but messy. However, if it can selectively activate some pathways while avoiding others, it becomes more precise.

This phenomenon is known as biased agonism.

The modified peptides in this study showed signs of biased signaling. They activated the main receptor pathways needed for function, but showed reduced activation of other pathways, such as those involving beta-arrestin proteins.

This is important because it suggests a possible path toward drugs that are not just effective, but also cleaner in their action.

Why Less Structure Can Sometimes Be Better

At first glance, it seems counterintuitive that breaking structural rules could improve drug performance. But biology often rewards balance rather than rigidity.

A molecule that is too rigid may interact too broadly or too strongly, triggering unwanted effects. A molecule with controlled flexibility, on the other hand, may interact more selectively.

By weakening the alpha helix, researchers may have unintentionally created peptides that explore a wider range of shapes. This flexibility might allow them to find just the right interactions needed to activate beneficial pathways while avoiding others.

Instead of one fixed key, it is as if the molecule becomes a “multi-angle key” that can still fit the lock, but in a more controlled way.

What This Means for Drug Design

This discovery expands the possibilities of how peptide medicines can be designed.

Traditionally, researchers tried to stabilize specific shapes, especially the alpha helix, to improve drug performance. Now, scientists may also consider the opposite strategy: introducing controlled flexibility to achieve better selectivity.

This could have major implications for diseases that rely on GPCR signaling, a large family of receptors involved in metabolism, appetite, bone growth, and many other essential functions.

If scientists can fine-tune how strongly and in what way these receptors are activated, they may be able to design drugs that are both more effective and have fewer side effects.

A Shift in Perspective

Scientific progress often happens when an assumption is challenged. In this case, the assumption was simple: peptide hormones must form a stable alpha helix to function.

The new findings do not completely reject this idea, but they show it is not the full story. Biology is more flexible than previously thought, and molecular shape is not a fixed requirement but part of a dynamic system.

This shift is subtle but important. It moves the focus from “What shape does this molecule need to be?” to “What kinds of interactions are actually necessary for the signal to work?”

The Bigger Picture

Beyond the technical details, this research reflects something broader about living systems. Biology is not built on rigid rules alone. It is built on adaptability.

Molecules can tolerate variation. Signals can be interpreted in multiple ways. And sometimes, breaking an expected rule does not destroy function—it refines it.

The discovery that peptide drugs can still activate receptors without fully maintaining their expected structure is a reminder of how much there is still to learn about the molecular language of life.

It also highlights an exciting future for medicine: one where drugs are not only designed to match biological systems, but to subtly reshape how those systems respond.

In that future, the goal is not just to copy nature’s signals, but to improve upon them.